Sector · Health & Nutrition
Specialty Bio-Ingredients
Available reports
Human Milk Oligosaccharides
Investor Brief
A 28-page sector note on Human Milk Oligosaccharides at the inflection point: a Chinese cost cohort now at near-parity with Western mature plants, the manufacturing-IP staircase running 2027 to 2035, and value migrating off the flagship 2'-FL into multi-HMO blends. Written from inside the industry, with a named, dated, falsifiable forward call on where the durable Western returns live..
Human Milk Oligosaccharides
Competitive & Commercial Landscape
The definitive map of the HMO competitive and commercial landscape: twelve chapters and six appendices, 38+ named exhibits and 100+ public-record citations. Supply read plant-by-plant, the cost stack built bottom-up, the IP cliff as a maintenance-fee schedule with named expiries through 2042, regulatory access named structure by jurisdiction by player, and health evidence graded trial-by-trial.
Coming next
Specialty Sweeteners
Allulose, tagatose, and rare sugars at the inflection: regulatory clearance, fermentation economics, and whether the next category re-rates the way HMO did.
What makes us knowledgeable about this sector
I have been close to the HMO category since 2016, when I joined Inbiose as Chief Commercial Officer. Over the next four years we reframed the company from a single 2'-FL ingredient to a diversified glycan platform; the team grew from fifteen to roughly fifty; the licensing and co-development agreements I led with global ingredient and FMCG majors became a major source of partner funding and helped attract over €15 million in growth equity. In 2024 I returned to lead the company — the mandate was to preserve the IP, the team, and investor confidence through a period of strategic transition. It held.
The HMO research we publish draws on that direct operating experience, on the work that preceded it across DuPont Industrial Biosciences and S-Biomedic, and on a warm network across the named Western incumbents, the Asian rising tier, and the buyer-side formula brands. The cost stacks, capacity matrices, and forward calls in the editions come from primary- source triangulation against that network — not from desk research.
Need this applied to your situation?
Strategic advisory in HMOs and adjacent specialty ingredients — sector diligence for PE investors, market-entry strategy for corporates, regulatory-path mapping, partner identification. Bespoke, confidential engagements.